Status:
RECRUITING
Acupuncture at the Sphenopalatine Ganglion in the Treatment of Moderate-to-severe Seasonal Allergic Rhinitis
Lead Sponsor:
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Collaborating Sponsors:
Aerospace 731 Hospital
Conditions:
Seasonal Allergic Rhinitis
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
Allergic rhinitis (AR) is an immunoglobulin E-mediated inflammatory disease1 caused by hypersensitivity of the immune system to an allergen, affecting 100 million people in Europe 2and 400 million of ...
Eligibility Criteria
Inclusion
- Age ≥18 years and ≤ 75 years;
- History of moderate to severe SAR symptoms (Visual analog scale(VAS) \>50 mm, range, 0 cm\[not at all bothersome\] to 100 mm\[extremely bothersome\]) for more than 4 days/weeks, and more than 4 consecutive weeks with at least two years' duration;
- Positive skin prick test to grass and birch pollen or/and serum-specific IgE test;
- Ability to complete the medical information form and sign a written informed consent.
Exclusion
- History or current evidence of perennial allergic rhinitis, acute sinusitis, allergic asthma, pneumonia; autoimmune disorders, or severe chronic inflammatory diseases;
- History of nasal rhinopolypus or abnormalities;
- Intake of antihistamines, anticholinergics, corticosteroids, decongestants, or antibiotics during the 1 month prior to beginning the study;
- History of systemically administered corticosteroids within 6 months or specific immunotherapy, allergy desensitization therapy within 1 year before enrollment;
- Serious uncontrolled blood coagulation disorder, cardiovascular disorder, severe hepatic/renal insufficiency or mental disorder;
- Pregnancy or planning for pregnancy;
- Known allergy, or contraindication to rescue medication or related drugs;
- Known phobia to acupuncture or having received acupuncture treatment, or sphenopalatine ganglion stimulation or other complementary and alternative medicine within 1 months prior to enrollment.
Key Trial Info
Start Date :
May 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT04815668
Start Date
May 1 2021
End Date
December 31 2026
Last Update
July 16 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
No.731 Hospital of China Aerospace Science and Industry Corporation
Beijing, China